company background image
SAPL

sanofi-aventis Pakistan KASE:SAPL Stock Report

Last Price

PK₨1.10k

Market Cap

PK₨10.6b

7D

-4.3%

1Y

41.8%

Updated

26 Sep, 2022

Data

Company Financials
SAPL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance1/6
Financial Health6/6
Dividends3/6

SAPL Stock Overview

sanofi-aventis Pakistan Limited manufactures and sells pharmaceuticals, consumer healthcare products, and vaccines primarily in Pakistan, Afghanistan, and internationally.

sanofi-aventis Pakistan Competitors

Price History & Performance

Summary of all time highs, changes and price drops for sanofi-aventis Pakistan
Historical stock prices
Current Share PricePK₨1,100.00
52 Week HighPK₨1,540.00
52 Week LowPK₨492.00
Beta0.66
1 Month Change-21.53%
3 Month Change18.98%
1 Year Change41.75%
3 Year Change124.49%
5 Year Change-38.03%
Change since IPO744.53%

Recent News & Updates

Shareholder Returns

SAPLPK PharmaceuticalsPK Market
7D-4.3%-1.7%-1.0%
1Y41.8%-25.8%-14.2%

Return vs Industry: SAPL exceeded the PK Pharmaceuticals industry which returned -27.2% over the past year.

Return vs Market: SAPL exceeded the PK Market which returned -16.3% over the past year.

Price Volatility

Is SAPL's price volatile compared to industry and market?
SAPL volatility
SAPL Average Weekly Movement9.8%
Pharmaceuticals Industry Average Movement3.3%
Market Average Movement4.9%
10% most volatile stocks in PK Market7.8%
10% least volatile stocks in PK Market3.2%

Stable Share Price: SAPL is more volatile than 90% of PK stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: SAPL's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of PK stocks.

About the Company

FoundedEmployeesCEOWebsite
1967869Asim Jamalhttps://www.sanofi.com.pk

sanofi-aventis Pakistan Limited manufactures and sells pharmaceuticals, consumer healthcare products, and vaccines primarily in Pakistan, Afghanistan, and internationally. It offers products for diabetes that include oral products under the Amaryl, Daonil, and Neodipar names, as well as insulins under the Toujeo, Lantus, SoloSTAR, and Apidra names; oncology products under the Thyrogen, Jevtana, Taxotere, Eloxatin, and Fludara names; nephrology products under the Renvela name; organ transplantation products under the Thymoglobulin name; urology products under the Xatral name; pain management products under the No-Spa and Muscoril; and antiemetic products under the Stemetil name. The company also provides products for allergy management under the Telfast, Telfast-D, Avil, Nasacort, Phenergan, and Tixylix names; products for sleep disorders under the Stilnox name; products for emergency care under the Haemaccel name; and cardiology products under the Plavix, CoPlavix, Aprovel, CoAprovel, Cordarone, Clexane, Tritace, CoTritace, Winstor, and Lasix/Lasoride names.

sanofi-aventis Pakistan Fundamentals Summary

How do sanofi-aventis Pakistan's earnings and revenue compare to its market cap?
SAPL fundamental statistics
Market CapPK₨10.61b
Earnings (TTM)PK₨650.98m
Revenue (TTM)PK₨17.33b

16.3x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SAPL income statement (TTM)
RevenuePK₨17.33b
Cost of RevenuePK₨12.34b
Gross ProfitPK₨4.99b
Other ExpensesPK₨4.34b
EarningsPK₨650.98m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)67.50
Gross Margin28.80%
Net Profit Margin3.76%
Debt/Equity Ratio2.4%

How did SAPL perform over the long term?

See historical performance and comparison

Dividends

2.7%

Current Dividend Yield

44%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is SAPL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SAPL?

Other financial metrics that can be useful for relative valuation.

SAPL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.6x
Enterprise Value/EBITDA6x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does SAPL's PE Ratio compare to its peers?

SAPL PE Ratio vs Peers
The above table shows the PE ratio for SAPL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average11.2x
FEROZ Ferozsons Laboratories
12xn/aPK₨8.8b
HINOON Highnoon Laboratories
10.6xn/aPK₨22.2b
AGP AGP
11.7xn/aPK₨20.6b
CPHL Citi Pharma
10.6xn/aPK₨6.9b
SAPL sanofi-aventis Pakistan
16.3xn/aPK₨10.6b

Price-To-Earnings vs Peers: SAPL is expensive based on its Price-To-Earnings Ratio (16.3x) compared to the peer average (11.2x).


Price to Earnings Ratio vs Industry

How does SAPL's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

Price-To-Earnings vs Industry: SAPL is good value based on its Price-To-Earnings Ratio (16.3x) compared to the Asian Pharmaceuticals industry average (21.8x)


Price to Earnings Ratio vs Fair Ratio

What is SAPL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SAPL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SAPL's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of SAPL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SAPL (PKR1100) is trading above our estimate of fair value (PKR657.42)

Significantly Below Fair Value: SAPL is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is sanofi-aventis Pakistan forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


17.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as sanofi-aventis Pakistan has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has sanofi-aventis Pakistan performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-10.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SAPL has high quality earnings.

Growing Profit Margin: SAPL's current net profit margins (3.8%) are lower than last year (6.7%).


Past Earnings Growth Analysis

Earnings Trend: SAPL's earnings have declined by 10.5% per year over the past 5 years.

Accelerating Growth: SAPL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SAPL had negative earnings growth (-37.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).


Return on Equity

High ROE: SAPL's Return on Equity (13%) is considered low.


Discover strong past performing companies

Financial Health

How is sanofi-aventis Pakistan's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: SAPL's short term assets (PKR8.4B) exceed its short term liabilities (PKR5.2B).

Long Term Liabilities: SAPL's short term assets (PKR8.4B) exceed its long term liabilities (PKR13.5M).


Debt to Equity History and Analysis

Debt Level: SAPL has more cash than its total debt.

Reducing Debt: SAPL's debt to equity ratio has reduced from 4.9% to 2.4% over the past 5 years.

Debt Coverage: SAPL's debt is well covered by operating cash flow (921.1%).

Interest Coverage: SAPL's interest payments on its debt are well covered by EBIT (330.6x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is sanofi-aventis Pakistan current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


2.73%

Current Dividend Yield

Dividend Yield vs Market

sanofi-aventis Pakistan Dividend Yield vs Market
How does sanofi-aventis Pakistan dividend yield compare to the market?
SegmentDividend Yield
Company (sanofi-aventis Pakistan)2.7%
Market Bottom 25% (PK)3.7%
Market Top 25% (PK)11.4%
Industry Average (Pharmaceuticals)4.1%
Analyst forecast in 3 Years (sanofi-aventis Pakistan)n/a

Notable Dividend: SAPL's dividend (2.73%) isn’t notable compared to the bottom 25% of dividend payers in the PK market (3.73%).

High Dividend: SAPL's dividend (2.73%) is low compared to the top 25% of dividend payers in the PK market (11.38%).


Stability and Growth of Payments

Stable Dividend: SAPL's dividend payments have been volatile in the past 10 years.

Growing Dividend: SAPL's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (44.4%), SAPL's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (38.9%), SAPL's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average board tenure


CEO

Asim Jamal

no data

Tenure

Dr. Asim Jamal has been the Chief Executive Officer, Managing Director and Executive Director of Sanofi Aventis Pakistan Limited since June 1, 2015. Dr. Jamal served as a Director of Business Development &...


Board Members

Experienced Board: SAPL's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of SAPL?
Owner TypeNumber of SharesOwnership Percentage
Private Companies141,1421.5%
General Public718,2537.4%
Individual Insiders1,328,15113.8%
Institutions2,357,74524.4%
Public Companies5,099,46952.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 18 shareholders own 92.55% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
52.87%
Sanofi
5,099,469PKR5.6b0%no data
19.1%
IGI Holdings Limited, Asset management Arm
1,841,739PKR2.0b0%6.57%
8.46%
Arshad Gohar
815,939PKR897.5m0%no data
4.63%
Syed Ali
446,435PKR491.1m0%no data
2.37%
National Investment Trust Limited
228,461PKR251.3m0%0.56%
2.12%
State Life Insurance Corporation of Pakistan Ltd, Asset Management Arm
204,099PKR224.5m0%1%
0.93%
AGT Holdings (Pvt.) Limited
89,700PKR98.7m0%no data
0.66%
Babar Ali Foundation, Endowment Arm
63,777PKR70.2m0%no data
0.53%
Ali Gohar & Co. (Pvt) Ltd
51,442PKR56.6m0%no data
0.24%
Perwin Ali
22,690PKR25.0m0%no data
0.2%
EFU General Insurance Limited, Asset Management Arm
19,200PKR21.1m0%3.35%
0.19%
Syeda Ali
18,714PKR20.6m0%no data
0.18%
Syed Ali
16,914PKR18.6m0%no data
0.077%
Naiyar Gohar
7,434PKR8.2m0%no data
0.0031%
UBL Fund Managers Limited
300PKR330.0k0%no data
0.0013%
National Bank of Pakistan, Asset Management Arm
129PKR141.9k0%no data
0.00041%
MCB Asset Management Company Limited
40PKR44.0k0%no data
0.00026%
Rehmatullah Wazir
25PKR27.5k0%no data

Company Information

sanofi-aventis Pakistan Limited's employee growth, exchange listings and data sources


Key Information

  • Name: sanofi-aventis Pakistan Limited
  • Ticker: SAPL
  • Exchange: KASE
  • Founded: 1967
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: PK₨10.609b
  • Shares outstanding: 9.64m
  • Website: https://www.sanofi.com.pk

Number of Employees


Location

  • sanofi-aventis Pakistan Limited
  • Plot 23
  • Korangi industrial Area
  • Karachi
  • 74900
  • Pakistan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SAPLKASE (Pakistan Stock Exchange Limited)YesOrdinary SharesPKPKRNov 1992

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/26 00:00
End of Day Share Price2022/09/26 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.